Literature DB >> 33403281

Synthesis of Benzyl 2-Deoxy-C-Glycosides.

Tsuyoshi Shinozuka1.   

Abstract

A synthetic method for benzyl 2-deoxy-C-glycosides has been developed. Palladium-catalyzed benzyl C-glycosylation of TIPS-protected 1-tributylstannyl glycals with a variety of benzyl bromides provided protected benzyl C-glycals. In this reaction, the use of PdCl2(dppe) promoted a clean reaction, whereas the reaction was accelerated by the addition of Na2CO3. The subsequent transformations provided a novel class of benzyl 2-deoxy-C-glycosides.
© 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 33403281      PMCID: PMC7774260          DOI: 10.1021/acsomega.0c04874

Source DB:  PubMed          Journal:  ACS Omega        ISSN: 2470-1343


Introduction

Oligosaccharides have been demonstrated to play multiple roles in biological reactions.[1] As oligosaccharides are linked by O-glycosidic bonds, they are vulnerable to acidic hydrolysis or enzymatic digestion, which is one of the major issues hindering their use as drugs. One plausible solution is the replacement of the O-glycosidic bond with C-glycoside, the utility of which has been proven by the development of sodium glucose cotransporter 2 (SGLT2) inhibitors. Specifically, many C-glycoside-based SGLT2 inhibitors are stable in human plasma, and these drugs have been introduced globally for the treatment of diabetes.[2] Although it is reported that benzyl C-glycosides of the phlorizin analog showed poor in vitro SGLT2 activity,[3] they are expected to exhibit a variety of biological activities owing to their more flexible nature than aryl C-glycosides. Although aryl C-glycosides are naturally occurring compounds and many synthetic methods are available,[4,5] only limited methods are available for the preparation of benzyl C-glycosides. Several groups reported the preparation of benzyl C-glycosides under harsh reaction conditions,[6] whereas an alternative method utilizing exomethylene sugar was reported.[7] The palladium-catalyzed coupling reaction of 1-tributylstannyl glucal and benzyl bromide or benzylsulfonyl chloride was reported with limited examples.[8] To investigate the biological roles of benzyl C-glycosides, the elaboration of synthetic methods for these compounds is needed. In this study, palladium-catalyzed coupling reactions of 1-tributylstannyl glycals with a variety of benzyl bromides were conducted, which provided adducts in fair to good yields, and subsequent manipulations provided a novel class of benzyl 2-deoxy-C-glycosides.[9]

Results and Discussion

Glycals 1 were protected as triisopropylsilyl (TIPS) ethers because stannylation requires a strong basic condition. TIPS protection of glycals 2a and 2b was carried out in the usual manner (Scheme ).[10,11] Because d-galactal 1c and l-fucal 1d could not be fully protected under this reaction condition, an alternative method was employed to obtain fully protected d-galactal 1c and l-fucal 1d using TIPSOTf. In this reaction, the effect of the base was critical because the usage of 2,6-lutidine led to a trace amount of 2c or 2d. As reported previously, TIPS-protected glycals 2a–2d were lithiated and stannylated to afford stannyl glycals 3a–3d.[10]
Scheme 1

Preparation of Stannyl Glycals 3

aMeONa, MeOH then TIPSCl, imidazole, DMF. bt-BuLi, THF, Bu3SnCl, −78 °C. cMeONa, MeOH then TIPSOTf, pyridine, CH2Cl2, 0 °C.

Preparation of Stannyl Glycals 3

aMeONa, MeOH then TIPSCl, imidazole, DMF. bt-BuLi, THF, Bu3SnCl, −78 °C. cMeONa, MeOH then TIPSOTf, pyridine, CH2Cl2, 0 °C. The coupling reaction conditions with TIPS-protected d-glucal 3a and 4-substituted benzyl bromide 4a were optimized because the usage of Pd(PPh3)4 as a palladium catalyst did not provide satisfactory results, as indicated in Table (entry 1). When Pd(PPh3)4 was used, the yield was poor despite the use of a variety of solvents (entries 1–5). A slight improvement of the yield was observed when PdCl2(PPh3)2 or Pd(OAc)2(PPh3)2 was used as a palladium catalyst, whereas PdCl2[1,1′-bis(diphenylphosphino)ferrocene (dppf)] did not improve the yield. When PdCl2[1,2-bis(diphenylphosphino)ethane (dppe)] or Pd(dppe)2 was employed, the reaction proceeded clearly. Under both reaction conditions, the reactions were sluggish with low yields (both 23%), and large amounts of 3a and 4a were recovered even after several days (entries 9 and 10). Thus, further optimization of the reaction conditions was attempted using PdCl2(dppe). The use of xylene improved the yield (entry 14), whereas increasing the amount of the palladium catalyst did not significantly improve the yield (entry 12). As the additives were sometimes effective for promoting the Stille coupling reaction,[12] the effect of the additives was examined. Organic bases such as Et3N prevented the reaction from proceeding (entry 15) and the addition of CuI gave a messy reaction with a trace amount of the adduct (entry 16).[13] The addition of LiCl was effective for the reaction and the yield was improved to 44% (entry 17).[14] A further improvement of yield was observed when Na2CO3 was employed (entry 16), and the adduct was isolated in 63%. The mechanistic aspects of how Na2CO3 promotes this reaction remain unclear. Because this reaction requires several days to achieve completion, the utilization of 3 equivalents of bromide shortened the reaction time to several hours and the yield reached 86% (entry 19).
Table 1

Optimization of the Conditions for Benzyl C-Glycosylationa

entrycatalystsolventadditive (equiv)yield (%)b
1Pd(PPh3)4toluenenone11
2Pd(PPh3)4THFnonetrace
3Pd(PPh3)4xylenenonetrace
4Pd(PPh3)4DMFnonetrace
5Pd(PPh3)41,4-dioxanenone7
6PdCl2(PPh3)2toluenenone23
7Pd(OAc)2(PPh3)2toluenenone30
8PdCl2(dppf)toluenenonetrace
9PdCl2(dppe)toluenenone23
10Pd(dppe)2toluenenone23
11Pd[P(o-Tol3)]4toluenenone10
12cPdCl2(dppe)toluenenone39
13PdCl2(dppe)DMFnonetrace
14PdCl2(dppe)xylenenone54
15PdCl2(dppe)tolueneEt3N (2.0)trace
16PdCl2(dppe)tolueneCuI (2.0)trace
17PdCl2(dppe)tolueneLiCl (2.0)44
18PdCl2(dppe)tolueneNa2CO3 (2.0)63
19dPdCl2(dppe)tolueneNa2CO3 (2.0)86

The reaction was performed using 3a (0.1 mmol), 4a (0.12 mmol), and the Pd catalyst (0.01 mmol) in the solvent (5 mL) under reflux unless otherwise noted.

Isolated yield.

0.5 equiv of the catalyst were used.

3.0 equiv of 4a were used.

The reaction was performed using 3a (0.1 mmol), 4a (0.12 mmol), and the Pd catalyst (0.01 mmol) in the solvent (5 mL) under reflux unless otherwise noted. Isolated yield. 0.5 equiv of the catalyst were used. 3.0 equiv of 4a were used. After optimizing the reaction conditions, the reactions of 1-tributylstannyl d-glucal 3a with several benzyl bromides 4 were performed. The result is summarized in Table . Although 3-substituted adduct 5b was isolated in fair yields, 2-substituted adduct 5c could not be obtained (entries 1 and 2). A variety of functional groups are tolerated under these reaction conditions, including ketone (entry 3), nitrile (entry 4), nitro (entry 5), and acetoxy groups (entry 9). The yield of adduct 5 with an electron-withdrawing substituent was better than that with an electron-releasing substituent. Ketone 5d, nitrile 5e, and nitro compound 5f displayed slightly better yields than tolyl analog 5g. The utilization of 3,4-disubstituted benzyl bromide 4j provided adduct 5j at 45% yield.
Table 2

Reaction with Various Benzyl Bromidesa

entry4 (Y)5yield (%)b
14b (3-CO2Me)5b71
24c (2-CO2Me)5c0
34d (4-COCH3)5d65
44e (4-CN)5e90
54f (4-NO2)5f69
64g (4-Me)5g56
74h (3-Cl)5h67
84i (H)5i85
94j (4-CO2Me, 3-OAc)5j45

All reactions were performed using 3a (0.1 mmol), 4 (0.30 mmol), PdCl2(dppe) (0.01 mmol), and Na2CO3 (0.20 mmol) in refluxing toluene (5 mL).

Isolated yield.

All reactions were performed using 3a (0.1 mmol), 4 (0.30 mmol), PdCl2(dppe) (0.01 mmol), and Na2CO3 (0.20 mmol) in refluxing toluene (5 mL). Isolated yield. Then, 1-tributylstannyl glycals 3b–3d were reacted with benzyl bromides 4a, 4b, 4e, 4i, and 4j, as indicated in Table . When 6-deoxy-1-tributylstannyl-l-glucal 3b was used, the yield of adduct 6 was excellent for all benzyl bromides excluding 4j. The yields of 4-substituted ester 6a, 3-analog 6b, and nitrile 6c approached 90%, whereas the unsubstituted benzyl analog 6i was obtained quantitatively. The yield of 3,4-disubstituted compound 6j was better than that of 5j (Table entry 9), and similarly modest yields were observed for the 3,4-disubstituted compounds 7j and 8j. When 1-tributylstannyl d-galactal 3c was employed, high yields were also obtained for ester 7a and unsubstituted compound 7i. Although a high yield was expected when sterically less-hindered 1-tributylstannyl l-fucal 3d was utilized, modest yields were confirmed for 4-substituted ester 8a, 3-analog 8b, and nitrile 8e, being lower than that of 3c. As adduct 8i was unstable, this instability may have affected the yield of 8. In fact, a small amount of adducts 8b, 8e, and 8j was decomposed after several days, which was confirmed by the 1HNMR spectra (see Supporting Information). Note that deprotected benzyl 2-deoxy-C-l-fucose derivatives 20a, 20b, and 20j are stable.
Table 3

Reactions of 3b, 3c, and 3d with 4a

  yield (%)b
4Yfrom 3bfrom 3cfrom 3d
4a4-CO2Me91 (6a)93 (7a)73 (8a)
4b3-CO2Me86 (6b)69 (7b)61 (8b)
4e4-CN86 (6e)77 (7e)70 (8e)
4iH99 (6i)92 (7i)-c (8i)
4j4-CO2Me, 3-OAc67 (6j)67 (7j)62 (8j)

All reactions were performed using 3 (0.10 mmol), 4 (0.30 mmol), PdCl2(dppe) (0.01 mmol), and Na2CO3 (0.20 mmol) in refluxing toluene (5 mL).

Isolated yield.

The adduct was unstable, and it decomposed after purification.

All reactions were performed using 3 (0.10 mmol), 4 (0.30 mmol), PdCl2(dppe) (0.01 mmol), and Na2CO3 (0.20 mmol) in refluxing toluene (5 mL). Isolated yield. The adduct was unstable, and it decomposed after purification. As various benzyl C-glycals were obtained, further transformations were conducted (Scheme ). The TIPS group was easily deprotected under usual conditions to provide glycals 9a, 12a, 15a, and 18a.[15] These glycals were subjected to hydrogenation to provide 2-deoxy glycosides 10a, 13a, 16a, and 19a.[8c] Note that the TIPS-protected d-glucal 5a was resistant to hydrogenation because of its steric bulkiness. Final saponification provided benzyl 2-deoxy-C-glycosides 11a, 14a, 17a, and 20a.[16] In the same manner, 2-deoxy-l-fucose analogs 20b and 20j were synthesized (Figure ). The stereochemistry was determined by observing NOE between hydrogen molecules in the 1, 3, and 5 positions in each sugar moiety in 21a–24a as indicated in Figure .
Scheme 2

Preparation of Benzyl 2-Deoxy-C-Glycosides 11a, 14a, 17a, and 20a

aTBAF, THF. bH2, Pd/C, THF. cNaOH, MeOH.

Figure 1

Structures of compounds 20b, 20j, and 21a–24a.

Structures of compounds 20b, 20j, and 21a–24a.

Preparation of Benzyl 2-Deoxy-C-Glycosides 11a, 14a, 17a, and 20a

aTBAF, THF. bH2, Pd/C, THF. cNaOH, MeOH.

Conclusions

In conclusion, a synthetic method for benzyl 2-deoxy-C-glycosides has been developed. A palladium-catalyzed coupling reaction with 1-tributylstannyl glycals and benzyl bromides proceeded clearly under the optimized conditions [0.1 equiv of PdCl2(dppe) and 2 equiv of Na2CO3 in refluxing toluene]. 3- or 4-Substituted or 3,4-disubstituted benzyl bromide gave the adducts in fair to good yields, whereas the 2-substituted analog was not obtained. These adducts were deprotected, hydrogenated, and saponified to provide a novel class of benzyl 2-deoxy-C-glycosides. This method is useful for synthesizing novel benzyl C-glycosides, which are expected to display a variety of biological activities.

Experimental Section

Starting reagents were purchased from commercial suppliers and were used without further purification, unless otherwise specified. Chromatographic elution was conducted under continuous monitoring by TLC using silica gel 60F254 (Merck & Co., Inc.) as the stationary phase and the elution solvent used in column chromatography as the mobile phase. A UV detector was used for detection. Silica gel SK-85 (230–400 mesh) or silica gel SK-34 (70–230 mesh), both of which were manufactured by Merck & Co., Inc., was used as the column-packing silica gel. 1H and 13C NMR spectra were obtained on Varian Unity 400 MHz spectrometers. Spectra were recorded in the indicated solvent at ambient temperature and chemical shifts are reported in ppm (δ) relative to the solvent peak. Resonance patterns are represented by the following notations: br (broad signal), s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). HRMS was conducted using an LC–MS system consisting of a Waters Xevo Quadropole-ToF MS and an Acquity UHPLC system.

1,5-Anhydro-2-deoxy-3,4,6-tris-O-[tri(propan-2-yl)silyl]-d-arabino-hex-1-enitol (2a)[10]

To a solution of 3,4,6-tri-O-acetyl-d-glucal (1a; 10.8 g, 40.0 mmol) in MeOH (80 mL) was added a solution of MeONa in MeOH (0.2 mL, 1.0 mmol) at room temperature. After the reaction mixture was stirred at room temperature for 2 h, the residue was concentrated under reduced pressure. To this residue was added DMF (80 mL), imidazole (27.2 g, 400 mmol), and TIPSCl (42 mL, 200 mmol), and the reaction mixture was stirred at 100 °C for 2 days. Water (50 mL) was added to the cooled reaction mixture, and the mixture was extracted several times with EtOAc. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After concentrating under reduced pressure, the residue was purified via silica gel chromatography to obtain 2a as a colorless oil (20.53 g, 83%). [α]D23 = −14.6 (c = 0.7, CHCl3); 1H NMR (400 MHz, CDCl3): δ 6.34 (1H, d, J = 6.6 Hz), 4.82–4.79 (1H, m), 4.25–4.22 (1H, m), 4.09–4.04 (2H, m), 3.96–3.94 (1H, m), 3.82 (1H, dd, J = 4.0, 11.5 Hz), 1.06–1.06 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 142.9 (CH), 100.4 (CH), 80.8 (CH), 70.3 (CH), 65.1 (CH), 62.1 (CH2), 18.1 (Me), 18.0 (Me), 12.5 (CH), 12.1 (CH); HRMS (FAB) m/z: [M – H]− calcd for C33H59O4Si3, 613.4504; found, 613.4485.

1,5-Anhydro-2,6-dideoxy-3,4-bis-O-[tri(propan-2-yl)silyl]-l-arabino-hex-1-enitol (2b)[11]

In the same manner in which 2a was prepared, the use of 3,4-di-O-acetyl-6-deoxy-l-glucal (1b; 5.02 g, 23.4 mmol) afforded 2b as a colorless oil (8.75 g, 85%). [α]D23 = 65.4 (c = 1.8, CHCl3); 1H NMR (400 MHz, CDCl3): δ 6.32 (1H, d, J = 6.3 Hz), 4.81 (1H, dt, J = 1.6, 5.6 Hz), 4.26 (1H, tq, J = 2.0, 7.1 Hz), 4.01 (1H, dt, J = 2.3, 4.7 Hz), 3.92 (1H, dd, J = 2.0, 3.7 Hz), 1.38 (3H, d, J = 7.2 Hz), 1.06–1.06 (42H, m); 13C NMR (67.8 MHz, CDCl3): δ 142.4 (CH), 100.4 (CH), 74.6 (CH), 73.5 (CH), 65.9 (CH), 18.1 (Me), 16.1 (Me), 12.6 (CH), 12.5 (CH); HRMS (FAB) m/z: [M – H]− calcd for C24H49O3Si2, 441.3220; found, 441.3182.

1,5-Anhydro-2-deoxy-3,4,6-tris-O-[tri(propan-2-yl)silyl]-d-lyxo-hex-1-enitol (2c)[11]

To a solution of 3,4,6-tri-O-acetyl-d-galactal (1c; 12.68 g, 46.6 mmol) in MeOH (80 mL) was added a solution of MeONa in MeOH (0.2 mL, 1.0 mmol) at room temperature. The reaction mixture was stirred for 2 h at room temperature and concentrated under reduced pressure. To this residue was added CH2Cl2 (80 mL), pyridine (30 mL, 372.8 mmol), and TIPSOTf (50 mL, 186.4 mmol) at 0 °C, and the reaction mixture was stirred for 3 days at room temperature. Water (50 mL) was added to the cooled reaction mixture, and the mixture was extracted several times with CH2Cl2. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After concentrating under reduced pressure, the residue was purified via silica gel chromatography to obtain 2c as a colorless oil (21.92 g, 76%). [α]D23 = −21.3 (c = 0.6, CHCl3); 1H NMR (400 MHz, CDCl3): δ 6.22 (1H, d, J = 6.0 Hz), 4.78 (1H, m), 4.20–4.06 (5H, m), 1.10–1.04 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 142.8 (CH), 102.4 (CH), 80.6 (CH), 70.3 (CH), 64.2 (CH), 60.8 (CH2), 18.3 (Me), 18.2 (Me), 18.0 (Me), 12.7 (CH), 12.1 (CH); HRMS (FAB) m/z: [M – H]− calcd for C33H59O4Si3, 613.4504; found, 613.4482.

1,5-Anhydro-2,6-dideoxy-3,4-bis-O-[tri(propan-2-yl)silyl]-l-lyxo-hex-1-enitol (2d)

In the same manner in which 2c was prepared, the use of 3,4-di-O-acetyl-l-fucal (1d; 14.90 g, 70.0 mmol) afforded 2d as a colorless oil (18.29 g, 59%). [α]D23 = 74.3 (c = 0.8, CHCl3); 1H NMR (400 MHz, CDCl3): δ 6.20 (1H, d, J = 6.2 Hz), 4.72 (1H, m), 4.38 (1H, m), 4.19 (1H, m), 4.05 (1H, m), 1.41 (3H, d, J = 6.7 Hz), 1.08–1.08 (42H, m); 13C NMR (67.8 MHz, CDCl3): δ 142.6 (CH), 102.3 (CH), 73.9 (CH), 70.8 (CH), 65.8 (CH), 18.3 (Me), 18.2 (Me), 12.9 (CH), 12.8 (CH); HRMS (FAB) m/z: [M – H]− calcd for C24H49O3Si2, 441.3220; found, 441.3220.

1,5-Anhydro-2-deoxy-1-(tributylstannyl)-3,4,6-tris-O-[tri(propan-2-yl)silyl]-d-arabino-hex-1-enitol (3a)[10]

To a solution of 2a (20.53 g, 33.4 mmol) in THF (150 mL) was added t-BuLi (81.0 mL, 133.6 mmol) at −78 °C under N2. After the reaction mixture was stirred at 0 °C for 1 h, Bu3SnCl (23.0 mL, 83.5 mmol) was added at −78 °C, and the reaction mixture was stirred at 0 °C for 1 h. The reaction was quenched with water (50 mL), and the mixture was extracted several times with EtOAc. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After concentrating under reduced pressure, the residue was purified via silica gel chromatography to obtain 3a as a colorless oil (15.84 g, 52%). [α]D23 = −23.2 (c = 0.8, CHCl3); 1H NMR (400 MHz, CDCl3): δ 4.83 (1H, dd, J = 1.9, 5.1 Hz), 4.11–4.06 (2H, m), 3.96 (1H, dd, J = 6.7, 10.9 Hz), 3.90 (1H, dd, J = 5.1, 10.9 Hz), 3.85–3.83 (1H, m), 1.60–1.27 (12H, m), 1.06–1.06 (63H, m), 0.94–0.85 (15H, m); 13C NMR (67.8 MHz, CDCl3): δ 162.4 (C), 111.3 (CH), 80.6 (CH), 70.3 (CH), 65.1 (CH), 62.5 (CH2), 29.0 (CH2), 27.4 (CH2), 27.3 (CH2), 18.2 (Me), 18.1 (Me), 13.7 (Me), 12.6 (CH), 12.5 (CH), 12.1 (CH), 9.5 (CH2); HRMS (FAB) m/z: [M – H]− calcd for 903.5560; found, 903.5577.

1,5-Anhydro-2,6-dideoxy-1-(tributylstannyl)-3,4-bis-O-[tri(propan-2-yl)silyl]-l-arabino-hex-1-enitol (3b)

In the same manner in which 3a was prepared, the use of 2b (5.50 g, 12.4 mmol) afforded 3b as a colorless oil (5.53 g, 61%). [α]D23 = 56.0 (c = 0.9, CHCl3); 1H NMR (400 MHz, CDCl3): δ 4.85 (1H, dd, J = 1.5, 4.5 Hz), 4.14 (1H, 1H, tq, J = 2.1, 7.3 Hz), 3.90 (1H, dd, J = 2.4, 4.6 Hz), 3.87 (1H, dd, J = 2.2, 4.1 Hz), 1.55–1.49 (6H, m), 1.36–1.26 (9H, m), 1.06–1.06 (42H, m), 0.94–0.86 (15H, m); 13C NMR (67.8 MHz, CDCl3): δ 161.5 (C), 111.5 (CH), 74.6 (CH), 73.7 (CH), 66.0 (CH), 29.1 (CH2), 29.0 (CH2), 27.3 (CH2), 18.2 (Me), 18.1 (Me), 16.5 (Me), 13.7 (Me), 12.6 (CH), 9.5 (CH2); HRMS (FAB) m/z: [M – H]− calcd for C36H75O3Si2Sn, 727.4277; found, 727.4236.

1,5-Anhydro-2-deoxy-1-(tributylstannyl)-3,4,6-tris-O-[tri(propan-2-yl)silyl]-d-lyxo-hex-1-enitol (3c)

In the same manner in which 3a was prepared, the use of 2c (21.61 g, 35.1 mmol) afforded 3c as a colorless oil (13.61 g, 43%). [α]D23 = −30.0 (c = 0.6, CHCl3); 1H NMR (400 MHz, CDCl3): δ 4.80 (1H, m), 4.15–4.01 (5H, m), 1.54–1.46 (6H, m), 1.35–1.27 (6H, m), 1.08–1.04 (63H, m), 0.96–0.85 (15H, m); 13C NMR (67.8 MHz, CDCl3): δ 162.0 (C), 112.8 (CH), 81.0 (CH), 70.5 (CH), 64.7 (CH), 61.3 (CH2), 29.0 (CH2), 27.3 (CH2), 18.3 (Me), 18.1 (Me), 13.7 (Me), 12.7 (CH), 12.1 (CH), 9.6 (CH2); HRMS (FAB) m/z: [M – H]− calcd for C45H95O4Si3Sn, 899.5560; found, 899.5578.

1,5-Anhydro-2,6-dideoxy-1-(tributylstannyl)-3,4-bis-O-[tri(propan-2-yl)silyl]-l-lyxo-hex-1-enitol (3d)

In the same manner in which 3a was prepared, the use of 2d (18.29 g, 41.3 mmol) afforded 3d as a colorless oil (11.5 g, 38%). [α]D23 = 61.0 (c = 0.8, CHCl3); 1H NMR (400 MHz, CDCl3): δ 4.76 (1H, m), 4.31 (1H, m), 4.10 (1H, m), 4.01 (1H, m), 1.58–1.48 (6H, m), 1.36–1.26 (9H, m), 1.08–1.08 (42H, m), 0.94–0.85 (15H, m); 13C NMR (67.8 MHz, CDCl3): δ 161.7 (C), 113.3 (CH), 74.1 (CH), 71.0 (CH), 66.3 (CH), 31.6 (CH2), 29.0 (CH2), 27.3 (CH2), 18.3 (Me), 14.2 (Me), 13.7 (Me), 13.0 (CH), 12.8 (CH), 9.6 (CH2); HRMS (FAB) m/z: [M – H]− calcd for C36H75O3Si2Sn, 731.4277; found, 731.4285.

General Procedure A: Palladium-Catalyzed Coupling Reactions

A solution of 1-tributylstannyl glycal 3 (0.10 mmol), benzyl bromide (0.30 mmol), PdCl2(dppe) (6 mg, 0.010 mmol), and Na2CO3 (21 mg, 0.20 mmol) in toluene (5 mL) was stirred at reflux for several hours under N2. For example, the reaction took 6 h to complete and result 5a. After the cooled reaction mixture was concentrated under reduced pressure, the residue was purified by silica gel chromatography to obtain 5, 6, 7, or 8.

2,6-Anhydro-1,3-dideoxy-1-[4-(methoxycarbonyl)phenyl]-4,5,7-tris-O-[tri(propan-2-yl)silyl]-d-arabino-hept-2-enitol (5a)

[α]D23 = −17.6 (c = 1.3, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 7.91 (2H, d, J = 8.1 Hz), 7.33 (2H, d, J = 8.1 Hz), 4.68 (1H, d, J = 4.7 Hz), 4.27–4.23 (1H, m), 4.03 (1H, dd, J = 2.0, 3.6 Hz), 4.00 (1H, dd, J = 2.1, 5.1 Hz), 3.94 (1H, dd, J = 7.7, 11.3 Hz), 3.90 (3H, s), 3.81 (1H, dd, J = 4.2, 11.3 Hz), 3.41 (2H, s), 1.03–1.03 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 167.2 (C), 151.7 (C), 143.9 (C), 129.5 (CH), 128.9 (CH), 128.1 (C), 98.0 (CH), 81.5 (CH), 69.6 (CH), 66.3 (CH), 62.2 (CH2), 51.9 (Me), 40.8 (CH2), 18.1 (Me), 18.0 (Me), 17.7 (Me), 12.5 (CH), 12.4 (CH), 12.0 (CH); HRMS (FAB) m/z: [M + K]+ calcd for C42H78O6Si3K, 801.4743; found, 801.4750.

2,6-Anhydro-1,3-dideoxy-1-[3-(methoxycarbonyl)phenyl]-4,5,7-tris-O-[tri(propan-2-yl)silyl]-d-arabino-hept-2-enitol (5b)

[α]D23 = −14.8 (c = 0.3, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 7.89 (1H, s), 7.87 (1H, d, J = 6.8 Hz), 7.49 (1H, d, J = 7.7 Hz), 7.31 (1H, t, J = 7.7 Hz), 4.65 (1H, d, J = 5.1 Hz), 4.25–4.21 (1H, m), 4.02 (1H, dd, J = 2.0, 3.6 Hz), 3.99 (1H, dd, J = 1.8, 4.9 Hz), 3.93 (1H, dd, J = 7.4, 11.0 Hz), 3.90 (3H, s), 3.81 (1H, dd, J = 4.2, 11.3 Hz), 3.39 (2H, s), 1.03–1.03 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 167.3 (C), 152.1 (C), 138.7 (C), 133.6 (CH), 130.2 (CH), 129.9 (C), 128.2 (CH), 127.5 (CH), 97.7 (CH), 81.4 (CH), 69.6 (CH), 66.4 (CH), 62.2 (CH2), 52.0 (Me), 40.7 (CH2), 18.2 (Me), 18.0 (Me), 12.5 (CH), 12.4 (CH), 12.0 (CH); HRMS (FAB) m/z: [M + H]+ calcd for C42H79O6Si3, 763.5185; found, 763.5180.

1-(4-Acetylphenyl)-2,6-anhydro-1,3-dideoxy-4,5,7-tris-O-[tri(propan-2-yl)silyl]-d-arabino-hept-2-enitol (5d)

[α]D23 = −17.5 (c = 0.6, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 7.89 (2H, d, J = 8.3 Hz), 7.36 (2H, d, J = 8.3 Hz), 4.70 (1H, d, J = 5.1 Hz), 4.26–4.20 (1H, m), 4.02 (1H, dd, J = 1.9, 3.5 Hz), 4.00 (1H, m), 3.94 (1H, dd, J = 7.8, 11.2 Hz), 3.81 (1H, dd, J = 4.2, 11.2 Hz), 3.41 (2H, s), 2.57 (3H, s), 1.04–1.04 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 197.9 (C), 151.6 (C), 144.3 (C), 135.3 (C), 129.0 (CH), 128.3 (CH), 98.0 (CH), 81.5 (CH), 69.6 (CH), 66.3 (CH), 62.3 (CH2), 40.9 (CH2), 26.6 (Me), 18.1 (Me), 18.0 (Me), 12.5 (CH), 12.4 (CH), 12.0 (CH); HRMS (FAB) m/z: [M + H]+ calcd for C42H79O5Si3, 747.5235; found, 747.5226.

2,6-Anhydro-1-(4-cyanophenyl)-1,3-dideoxy-4,5,7-tris-O-[tri(propan-2-yl)silyl]-d-arabino-hept-2-enitol (5e)

[α]D23 = −17.7 (c = 0.6, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 7.52 (2H, d, J = 8.1 Hz), 7.38 (2H, d, J = 8.2 Hz), 4.73 (1H, dd, J = 1.4, 5.1 Hz), 4.26–4.23 (1H, m), 4.01–3.99 (2H, m), 3.95 (1H, dd, J = 7.8, 11.3 Hz), 3.79 (1H, dd, J = 4.0, 11.3 Hz), 3.41 (2H, s), 1.04–1.04 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 151.0 (C), 144.2 (C), 132.0 (CH), 129.6 (CH), 119.2 (C), 110.0 (C), 98.4 (CH), 81.6 (CH), 69.5 (CH), 66.2 (CH), 62.2 (CH2), 41.0 (CH2), 18.2 (Me), 18.1 (Me), 18.0 (Me), 12.5 (CH), 12.4 (CH), 12.0 (CH); HRMS (FAB) m/z: [M – H]− calcd for C41H74NO4Si3, 728.4926; found, 728.4927.

2,6-Anhydro-1,3-dideoxy-1-(4-nitrophenyl)-4,5,7-tris-O-[tri(propan-2-yl)silyl]-d-arabino-hept-2-enitol (5f)

[α]D23 = −20.0 (c = 0.3, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 8.10 (2H, d, J = 8.7 Hz), 7.43 (2H, d, J = 8.7 Hz), 4.76 (1H, d, J = 6.8 Hz), 4.27–4.23 (1H, m), 4.02–4.00 (2H, m), 3.96 (1H, dd, J = 7.8, 11.3 Hz), 3.79 (1H, dd, J = 4.0, 11.3 Hz), 3.45 (2H, s), 1.04–1.04 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 150.9 (C), 146.6 (C), 146.4 (C), 129.6 (CH), 123.4 (CH), 98.5 (CH), 81.7 (CH), 69.5 (CH), 66.2 (CH), 62.2 (CH2), 40.8 (CH2), 18.2 (Me), 18.1 (Me), 18.0 (Me), 12.4 (CH), 12.3 (CH), 12.0 (CH); HRMS (FAB) m/z: [M – H]− calcd for C40H74NO6Si3, 748.4824; found, 748.4825.

2,6-Anhydro-1,3-dideoxy-1-(4-methylphenyl)-4,5,7-tris-O-[tri(propan-2-yl)silyl]-d-arabino-hept-2-enitol (5g)

[α]D23 = −14.6 (c = 0.4, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 7.13 (2H, d, J = 7.9 Hz), 7.04 (2H, d, J = 7.9 Hz), 4.62 (1H, dd, J = 0.9, 5.1 Hz), 4.26–4.22 (1H, m), 4.03 (1H, dd, J = 1.9, 3.7 Hz), 4.00 (1H, dd, J = 1.9, 5.1 Hz), 3.93 (1H, dd, J = 7.4, 11.1 Hz), 3.83 (1H, dd, J = 8.9, 11.0 Hz), 3.32 (2H, s), 2.30 (3H, s), 1.03–1.03 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 152.7 (C), 135.4 (C), 135.2 (C), 128.8 (CH), 97.4 (CH), 81.3 (CH), 69.7 (CH), 66.5 (CH), 62.3 (CH2), 40.3 (CH2), 21.0 (Me), 18.2 (Me), 18.1 (Me), 18.0 (Me), 12.5 (CH), 12.4 (CH), 12.0 (CH); HRMS (FAB) m/z: M+• calcd for C41H78O4Si3, 718.5208; found, 718.5193.

2,6-Anhydro-1-(3-chlorophenyl)-1,3-dideoxy-4,5,7-tris-O-[tri(propan-2-yl)silyl]-d-arabino-hept-2-enitol (5h)

[α]D23 = −16.6 (c = 0.5, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 7.23 (1H, s), 7.15 (3H, d, J = 1.2 Hz), 4.66 (1H, d, J = 4.8 Hz), 4.26–4.23 (1H, m), 4.03 (1H, dd, J = 1.3, 3.2 Hz), 4.01–3.99 (1H, m), 3.94 (1H, dd, J = 7.4, 11.1 Hz), 3.84 (1H, dd, J = 4.4, 11.0 Hz), 3.33 (2H, s), 1.04–1.04 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 151.8 (C), 140.4 (C), 133.9 (C), 129.3 (CH), 128.9 (CH), 127.1 (CH), 126.3 (CH), 97.9 (CH), 81.4 (CH), 69.6 (CH), 66.3 (CH), 62.2 (CH2), 40.5 (CH2), 18.2 (Me), 18.1 (Me), 18.0 (Me), 12.5 (CH), 12.4 (CH), 12.0 (CH); HRMS (FAB) m/z: [M – H]− calcd for C40H74O4ClSi3, 737.4583; found, 737.4598.

2,6-Anhydro-1,3-dideoxy-1-phenyl-4,5,7-tris-O-[tri(propan-2-yl)silyl]-d-arabino-hept-2-enitol (5i)

[α]D23 = −17.1 (c = 0.2, CH2Cl2); 1H NMR (400 MHz, CDCl3): δ 7.26–7.21 (3H, m), 7.19–7.14 (2H, m), 4.63 (1H, d, J = 4.8 Hz), 4.27–4.23 (1H, m), 4.04–4.03 (1H, m), 4.01–3.99 (1H, m), 3.95 (1H, dd, J = 7.3, 11.0 Hz), 3.84 (1H, dd, J = 4.4, 11.0 Hz), 3.37 (2H, s), 1.03–1.03 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 152.5 (C), 138.3 (C), 128.9 (CH), 128.1 (CH), 126.0 (CH), 97.6 (CH), 81.3 (CH), 69.7 (CH), 66.5 (CH), 62.3 (CH2), 40.7 (CH2), 18.2 (Me), 18.1 (Me), 18.0 (Me), 12.5 (CH), 12.4 (CH), 12.1 (CH); HRMS (FAB) m/z: [M – H]− calcd for C40H75O4Si3, 703.4973; found, 703.4967.

1-[3-(Acetyloxy)-4-(methoxycarbonyl)phenyl]-2,6-anhydro-1,3-dideoxy-4,5,7-tris-O-[tri(propan-2-yl)silyl]-d-arabino-hept-2-enitol (5j)

[α]D23 = −16.4 (c = 1.8, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.90 (1H, d, J = 8.1 Hz), 7.26 (1H, s), 7.21 (1H, dd, J = 1.3, 8.1 Hz), 6.99 (1H, d, J = 1.3 Hz), 4.72 (1H, d, J = 4.8 Hz), 4.25 (1H, ddd, J = 2.2, 4.5, 7.3 Hz), 4.04 (1H, dd, J = 1.5, 1.8 Hz), 4.01 (1H, dd, J = 1.7, 4.8 Hz), 3.95 (1H, dd, J = 7.7, 11.2 Hz), 3.85 (3H, s), 3.83 (1H, dd, J = 4.4, 11.2 Hz), 3.40 (2H, s), 2.32 (3H, s), 1.04–1.04 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 169.7 (C), 165.0 (C), 151.0 (C), 150.7 (C), 145.6 (C), 131.6 (CH), 126.5 (CH), 123.9 (CH), 120.8 (C), 98.5 (CH), 81.5 (CH), 69.5 (CH), 66.3 (CH), 62.2 (CH2), 52.0 (Me), 40.6 (CH2), 21.0 (Me, Ac), 18.2 (Me), 18.1 (Me), 18.0 (Me), 12.4 (CH), 12.1 (CH); HRMS (FAB) m/z: [M + Na]+ calcd for C44H80O8Si3Na, 843.5059; found, 843.5048.

2,6-Anhydro-1,3,7-trideoxy-1-[4-(methoxycarbonyl)phenyl]-4,5-bis-O-[tri(propan-2-yl)silyl]-l-arabino-hept-2-enitol (6a)

[α]D23 = 49.3 (c = 0.7, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.92 (2H, d, J = 8.3 Hz), 7.33 (2H, d, J = 8.3 Hz), 4.75 (1H, d, J = 4.9 Hz), 4.27 (1H, tq, J = 2.0, 7.2 Hz), 4.08–4.06 (1H, m), 3.90 (3H, s), 3.88–3.87 (1H, m), 3.40 (2H, s), 1.29 (3H, d, J = 7.2 Hz), 1.05–1.05 (42H, m); 13C NMR (67.8 MHz, CDCl3): δ 167.3 (C), 150.7 (C), 144.0 (C), 129.5 (CH), 128.8 (CH), 128.1 (C), 98.2 (CH), 75.2 (CH), 72.7 (CH), 67.0 (CH), 52.0 (Me), 41.0 (CH2), 18.2 (Me), 18.1 (Me), 16.1 (Me), 12.5 (CH); HRMS (FAB) m/z: [M + Na]+ calcd for C33H58O5Si2Na, 613.3721; found, 613.3715.

2,6-Anhydro-1,3,7-trideoxy-1-[3-(methoxycarbonyl)phenyl]-4,5-bis-O-[tri(propan-2-yl)silyl]-l-arabino-hept-2-enitol (6b)

[α]D23 = 48.3 (c = 0.8, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.92 (1H, s), 7.87 (1H, d, J = 7.7 Hz), 7.48 (1H, d, J = 7.6 Hz), 7.32 (1H, d, J = 7.6 Hz), 4.72 (1H, d, J = 5.1 Hz), 4.26 (1H, tq, J = 1.8, 7.3 Hz), 4.05 (1H, dd, J = 2.4, 5.0 Hz), 3.90 (3H, s), 3.87 (1H, dd, J = 1.8, 3.5 Hz), 3.39 (2H, s), 1.29 (3H, d, J = 7.3 Hz), 1.05–1.05 (42H, m); 13C NMR (67.8 MHz, CDCl3): δ 167.3 (C), 151.2 (C), 138.8 (C), 133.4 (CH), 130.1 (CH), 128.2 (CH), 128.0 (C), 127.5 (CH), 97.9 (CH), 75.2 (CH), 72.8 (CH), 67.1 (CH), 52.0 (Me), 40.8 (CH2), 18.2 (Me), 18.1 (Me), 16.0 (Me), 12.5 (CH); HRMS (FAB) m/z: M+• calcd for C33H58O5Si2, 590.3823; found, 590.3834.

2,6-Anhydro-1-(4-cyanophenyl)-1,3,7-trideoxy-4,5-bis-O-[tri(propan-2-yl)silyl]-l-arabino-hept-2-enitol (6e)

[α]D23 = 50.0 (c = 0.4, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.54 (2H, d, J = 8.1 Hz), 7.38 (2H, d, J = 8.3 Hz), 4.77 (1H, dd, J = 0.9, 5.0 Hz), 4.28 (1H, tq, J = 1.9, 7.3 Hz), 4.08–4.06 (1H, m), 3.88 (1H, dd, J = 2.0, 3.6 Hz), 3.40 (2H, s), 1.30 (3H, d, J = 7.2 Hz), 1.06–1.06 (42H, m); 13C NMR (67.8 MHz, CDCl3): δ 150.1 (C), 144.3 (C), 131.9 (CH), 129.5 (CH), 119.2 (C), 110.0 (C), 98.5 (CH), 75.4 (CH), 72.5 (CH), 66.9 (CH), 41.2 (CH2), 18.2 (Me), 18.1 (Me), 16.1 (Me), 12.5 (CH); HRMS (FAB) m/z: [M + Na]+ calcd for C32H55NO3Si2Na, 580.3618; found, 580.3617.

2,6-Anhydro-1,3,7-trideoxy-1-phenyl-4,5-bis-O-[tri(propan-2-yl)silyl]-l-arabino-hept-2-enitol (6i)

[α]D23 = 51.3 (c = 0.4, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.52–7.15 (5H, m), 4.70 (1H, d, J = 5.1 Hz), 4.27 (1H, tq, J = 2.1, 7.2 Hz), 4.08–4.06 (1H, m), 3.88 (1H, dd, J = 2.0, 3.7 Hz), 3.36 (2H, s), 1.30 (3H, d, J = 6.8 Hz), 1.05–1.05 (42H, m); 13C NMR (67.8 MHz, CDCl3): δ 151.6 (C), 138.3 (C), 128.8 (CH), 128.1 (CH), 126.1 (CH), 97.7 (CH), 75.1 (CH), 72.9 (CH), 67.2 (CH), 40.9 (CH2), 18.1 (Me), 16.1 (Me), 12.6 (CH), 12.5 (CH); HRMS (FAB) m/z: M+• calcd for C31H56O3Si2, 532.3768; found, 532.3777.

1-[3-(Acetyloxy)-4-(methoxycarbonyl)phenyl]-2,6-anhydro-1,3,7-trideoxy-4,5-bis-O-[tri(propan-2-yl)silyl]-l-arabino-hept-2-enitol (6j)

[α]D23 = 47.2 (c = 1.0, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.91 (1H, d, J = 8.1 Hz), 7.21 (1H, dd, J = 1.5, 8.1 Hz), 7.01 (1H, d, J = 1.2 Hz), 4.78 (1H, d, J = 5.0 Hz), 4.27 (1H, tq, J = 1.9, 7.1 Hz), 4.07 (1H, dd, J = 2.5, 5.0 Hz), 3.88 (1H, dd, J = 1.9, 3.6 Hz), 3.85 (3H, s), 3.39 (2H, s), 2.33 (3H, s), 1.28 (3H, d, J = 7.1 Hz), 1.06–1.06 (42H, m); 13C NMR (67.8 MHz, CDCl3): δ 169.7 (C), 165.0 (C), 150.7 (C), 150.1 (C), 145.7 (C), 131.6 (CH), 126.4 (CH), 123.9 (CH), 120.7 (C), 98.5 (CH), 75.2 (CH), 72.6 (CH), 66.9 (CH), 52.0 (Me), 40.8 (CH2), 21.0 (Me), 18.2 (Me), 18.1 (Me), 16.0 (Me), 12.5 (CH); HRMS (FAB) m/z: [M + Na]+ calcd for C35H60O7Si2Na, 671.3775; found, 671.3762.

2,6-Anhydro-1,3-dideoxy-1-[4-(methoxycarbonyl)phenyl]-4,5,7-tris-O-[tri(propan-2-yl)silyl]-d-lyxo-hept-2-enitol (7a)

[α]D23 = −23.5 (c = 1.0, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.94 (2H, d, J = 8.3 Hz), 7.29 (2H, d, J = 8.3 Hz), 4.55–4.45 (1H, m), 4.29–3.99 (5H, m), 3.91 (3H, s), 3.35 (2H, s), 1.08–1.01 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 167.2 (C), 152.4 (C), 143.3 (C), 129.6 (CH), 129.2 (CH), 128.3 (C), 99.9 (CH), 81.1 (CH), 70.0 (CH), 64.7 (CH), 61.2 (CH2), 52.0 (Me), 40.3 (CH2), 18.3 (Me), 18.2 (Me), 18.0 (Me), 12.6 (CH), 12.1 (CH); HRMS (FAB) m/z: [M + Na]+ calcd for C42H78O6Si3Na, 785.5004; found, 785.4984.

2,6-Anhydro-1,3-dideoxy-1-[3-(methoxycarbonyl)phenyl]-4,5,7-tris-O-[tri(propan-2-yl)silyl]-d-lyxo-hept-2-enitol (7b)

[α]D23 = −19.7 (c = 1.4, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.89 (1H, d, J = 7.9 Hz), 7.87 (1H, s), 7.44 (1H, d, J = 7.6 Hz), 7.34 (1H, t, J = 7.6 Hz), 4.51–4.36 (1H, m), 4.34–3.99 (5H, m), 3.91 (3H, s), 3.35 (2H, s), 1.08–1.02 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 167.2 (C), 152.8 (C), 138.1 (C), 133.9 (CH), 130.4 (CH), 130.2 (C), 128.3 (CH), 127.8 (CH), 99.8 (CH), 81.0 (CH), 70.0 (CH), 64.6 (CH), 61.2 (CH2), 52.0 (Me), 40.0 (CH2), 18.3 (Me), 18.0 (Me), 12.6 (CH), 12.1 (CH); HRMS (FAB) m/z: [M + Na]+ calcd for C42H78O6Si3Na, 785.5004; found, 785.4996.

2,6-Anhydro-1-(4-cyanophenyl)-1,3-dideoxy-4,5,7-tris-O-[tri(propan-2-yl)silyl]-d-lyxo-2-enitol (7e)

[α]D23 = −29.2 (c = 2.2, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.55 (2H, d, J = 8.1 Hz), 7.34 (2H, d, J = 8.2 Hz), 4.62–4.42 (1H, m), 4.38–3.90 (5H, m), 3.35 (2H, s), 1.08–1.01 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 151.7 (C), 143.6 (C), 132.1 (CH), 129.9 (CH), 119.1 (C), 110.3 (C), 100.2 (CH), 81.1 (CH), 69.9 (CH), 64.6 (CH), 61.2 (CH2), 40.4 (CH2), 18.3 (Me), 18.2 (Me), 18.0 (Me), 12.6 (CH), 12.0 (CH); HRMS (FAB) m/z: [M – H]− calcd for C41H74NO4Si3, 728.4926; found, 728.4939.

2,6-Anhydro-1,3-dideoxy-1-phenyl-4,5,7-tris-O-[tri(propan-2-yl)silyl]-d-lyxo-hept-2-enitol (7i)

[α]D23 = −20.2 (c = 1.4, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.30–7.18 (5H, m), 4.48–4.36 (1H, m), 4.32–3.98 (5H, m), 3.31 (2H, s), 1.10–1.02 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 153.3 (C), 137.7 (C), 129.2 (CH), 128.2 (CH), 126.3 (CH), 99.5 (CH), 80.9 (CH), 70.0 (CH), 64.7 (CH), 61.3 (CH2), 40.1 (CH2), 18.2 (Me), 18.0 (Me), 12.6 (CH), 12.1 (CH); HRMS (FAB) m/z: [M – Na]− calcd for C40H75O4Si3, 703.4973; found, 703.4985.

1-[3-(Acetyloxy)-4-(methoxycarbonyl)phenyl]-2,6-anhydro-1,3-dideoxy-4,5,7-tris-O-[tri(propan-2-yl)silyl]-d-lyxo-hept-2-enitol (7j)

[α]D23 = −16.5 (c = 0.9, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.92 (1H, d, J = 8.1 Hz), 7.18 (1H, dd, J = 1.2, 8.1 Hz), 6.96 (1H, d, J = 1.3 Hz), 4.54 (1H, m), 4.27–4.02 (5H, m), 3.86 (3H, s), 3.34 (2H, s), 2.34 (3H, s), 1.08–1.02 (63H, m); 13C NMR (67.8 MHz, CDCl3): δ 169.7 (C), 164.9 (C), 151.7 (C), 150.7 (C), 144.8 (C), 131.7 (CH), 126.8 (CH), 124.3 (CH), 121.0 (C), 100.1 (CH), 81.0 (CH), 69.9 (CH), 64.5 (CH), 61.1 (CH2), 52.0 (Me), 40.1 (CH2), 21.0 (Me), 18.2 (Me), 18.1 (Me), 17.9(Me), 12.6(CH), 12.0(CH); HRMS (FAB) m/z: M+• calcd for C44H80O8Si3, 820.5161; found, 820.5167.

2,6-Anhydro-1,3,7-trideoxy-1-[4-(methoxycarbonyl)phenyl]-4,5-bis-O-[tri(propan-2-yl)silyl]-l-lyxo-hept-2-enitol (8a)

[α]D23 = 74.4 (c = 0.6, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.95 (2H, d, J = 8.1 Hz), 7.30 (2H, d, J = 8.2 Hz), 4.54 (1H, m), 4.37 (1H, m), 4.17 (1H, m), 4.09 (1H, m), 3.91 (3H, s), 3.34 (2H, s), 1.32 (3H, d, J = 6.7 Hz), 1.08–1.05 (42H, m); 13C NMR (67.8 MHz, CDCl3): δ 167.2 (C), 151.6 (C), 143.6 (C), 129.5 (CH), 129.0 (CH), 128.2 (C), 100.0 (CH), 74.1 (CH), 70.5 (CH), 66.4 (CH), 52.0 (Me), 40.3 (CH2), 18.3 (Me), 18.2 (Me), 14.1 (Me), 12.9 (CH), 12.7 (CH); HRMS (FAB) m/z: [M – H]− calcd for C33H57O5Si2, 589.3745; found, 589.3751.

2,6-Anhydro-1,3,7-trideoxy-1-[3-(methoxycarbonyl)phenyl]-4,5-bis-O-[tri(propan-2-yl)silyl]-l-lyxo-hept-2-enitol (8b)

A small amount of the adduct 8b was decomposed after several days, which was confirmed using the 1HNMR spectra (see Supporting Information). [α]D23 = 53.2 (c = 1.2, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.90 (1H, s), 7.89 (1H, d, J = 6.5 Hz), 7.44 (1H, d, J = 7.7 Hz), 7.35 (1H, t, J = 7.1 Hz), 4.53 (1H, m), 4.35 (1H, m), 4.17 (1H, m), 4.02 (1H, m), 3.91 (3H, s), 3.33 (2H, s), 1.33 (3H, d, J = 6.7 Hz), 1.08–1.05 (42H, m); 13C NMR (67.8 MHz, CDCl3): δ 167.2 (C), 152.0 (C), 138.4 (C), 133.7 (CH), 130.2 (CH), 128.2 (CH), 127.7 (CH), 99.9 (CH), 74.1 (CH), 70.6 (CH), 65.9 (CH), 52.0 (Me), 40.1 (CH2), 18.3 (Me), 18.2 (Me), 13.6 (Me), 12.9 (CH), 12.7 (CH); HRMS (FAB) m/z: [M – H]− calcd for C33H57O5Si2, 589.3745; found, 589.3721.

2,6-Anhydro-1-(4-cyanophenyl)-1,3,7-trideoxy-4,5-bis-O-[tri(propan-2-yl)silyl]-l-lyxo-hept-2-enitol (8e)

A small amount of the adduct 8e was decomposed after several days, which was confirmed using the 1H NMR spectra (see Supporting Information). [α]D23 = 65.6 (c = 0.8, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.56 (2H, d, J = 8.3 Hz), 7.35 (2H, d, J = 8.2 Hz), 4.53 (1H, m), 4.40 (1H, m), 4.16 (1H, m), 4.15 (1H, m), 3.34 (2H, s), 1.30 (3H, d, J = 6.7 Hz), 1.08–1.05 (42H, m); 13C NMR (67.8 MHz, CDCl3): δ 151.0 (C), 143.8 (C), 132.0 (CH), 129.7 (CH), 119.1 (C), 110.2 (C), 100.6 (CH), 74.2 (CH), 70.5 (CH), 66.4 (CH), 40.4 (CH2), 18.5 (Me), 18.2 (Me), 13.5 (Me), 13.0 (CH), 12.7 (CH); HRMS (FAB) m/z: [M – H]− calcd for C32H56NO3Si2, 558.3799; found, 558.3785.

1-[3-(Acetyloxy)-4-(methoxycarbonyl)phenyl]-2,6-anhydro-1,3,7-trideoxy-4,5-bis-O-[tri(propan-2-yl)silyl]-l-lyxo-hept-2-enitol (8j)

A small amount of the adduct 8j was decomposed after several days, which was confirmed using the 1HNMR spectra (see Supporting Information). [α]D23 = 44.0 (c = 0.8, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.93 (1H, d, J = 8.1 Hz), 7.18 (1H, dd, J = 1.3, 8.1 Hz), 6.99 (1H, d, J = 1.3 Hz), 4.59 (1H, m), 4.38 (1H, m), 4.17 (1H, m), 4.00 (1H, m), 3.86 (3H, s), 3.32 (2H, s), 2.34 (3H, s), 1.32 (3H, d, J = 6.7 Hz), 1.08–1.06 (42H, m); 13C NMR (67.8 MHz, CDCl3): δ 169.7 (C), 164.9 (C), 150.9 (C), 150.7 (C), 145.2 (C), 131.6 (CH), 126.6 (CH), 124.1 (CH), 120.9 (C), 100.4 (CH), 74.1 (CH), 70.5 (CH), 67.0 (CH), 52.0 (Me), 40.1 (CH2), 21.0 (Me), 18.3 (Me), 18.2 (Me), 13.6 (Me), 12.8 (CH), 12.7 (CH); HRMS (FAB) m/z: [M – H]− calcd for C35H59O7Si2, 647.3799; found, 647.3778.

General Procedure B: Deprotection, Followed by Hydrogenation–Saponification

The solution of the coupled products 5, 6, 7, or 8 (0.60 mmol) in THF (5.0 mL) was added to 1.0 M THF solution of TBAF (5.0 mL, 5.0 mmol), and the reaction mixture was stirred at room temperature for several hours. The reaction was quenched with water (10 mL), and the mixture was extracted several times with EtOAc. The combined organic layers were washed with water, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude methyl ester 9, 12, 15, or 18. The solution of 9, 12, 15, or 18 and 10% Pd/C (13 mg) in THF (5 mL) was stirred at room temperature under H2 for several hours. The catalyst was removed via filtration, and the filtrate was concentrated under reduced pressure to obtain crude 10, 13, 16, or 19. Crude 10, 13, 16, or 19 was dissolved in MeOH (5.0 mL) and 1 M aqueous solution of NaOH (5.0 mL, 5.0 mmol) was added. The resulting reaction mixture was stirred at room temperature for several hours. HCl (1 M) was added to the reaction mixture and the mixture was concentrated under reduced pressure. The residue purified by column chromatography afforded benzyl 2-deoxy-C-glycoside 11, 14, 17, or 20.

2,6-Anhydro-1-(4-carboxyphenyl)-1,3-dideoxy-d-gluco-heptitol (11a)

Compound 11a was prepared according to general procedure B (yield, 38%; 3 steps). [α]D23 = 10.0 (c = 0.4, MeOH); 1H NMR (400 MHz, D2O): δ 7.62 (2H, d, J = 8.2 Hz), 7.15 (2H, d, J = 8.2 Hz), 3.64 (1H, dd, J = 1.9, 12.2 Hz), 3.68–3.61 (1H, m), 3.47 (1H, dd, J = 5.5, 12.2 Hz), 3.44 (1H, ddd, J = 5.2, 8.4, 11.5 Hz), 3.11 (1H, ddd, J = 2.2, 5.8, 9.2 Hz), 3.05 (1H, t, J = 8.6 Hz), 2.78 (1H, dd, J = 7.0, 13.9 Hz), 2.63 (1H, dd, J = 6.2, 13.9 Hz), 1.82 (1H, ddd, J = 1.4, 5.1, 12.7 Hz), 1.21 (1H, q, J = 12.9 Hz); 13C NMR (67.8 MHz, D2O): δ 177.7 (C), 143.8 (C), 136.7 (C), 131.4 (CH), 131.3 (CH), 82.1 (CH), 78.5 (CH), 74.3 (CH), 73.7 (CH), 63.4 (CH2), 42.9 (CH2), 40.3 (CH2); HRMS (FAB) m/z: [M – H]− calcd for C14H17O6, 281.1025; found, 281.1026.

2,6-Anhydro-1-(4-carboxyphenyl)-1,3,7-trideoxy-l-gluco-heptitol (14a)

Compound 14a was prepared according to general procedure B (yield, 48%; 3 steps). [α]D23 = 13.6 (c = 0.3, MeOH); 1H NMR (400 MHz, D2O): δ 7.75 (2H, d, J = 8.2 Hz), 7.20 (2H, d, J = 8.1 Hz), 3.70–3.64 (1H, m), 3.42 (1H, ddd, J = 5.1, 9.2, 11.4 Hz), 3.13 (1H, dq, J = 6.1, 9.0 Hz), 2.85 (1H, t, J = 9.2 Hz), 2.74 (1H, dd, J = 7.6, 14.1 Hz), 2.67 (1H, dd, J = 5.7, 14.2 Hz), 1.86 (1H, ddd, J = 1.2, 5.1, 13.0 Hz), 1.24 (1H, q, J = 11.6 Hz), 1.03 (3H, d, J = 6.1 Hz); 13C NMR (67.8 MHz, D2O): δ 173.6 (C), 146.2 (C), 132.0 (CH), 131.7 (CH), 79.1 (CH), 78.4 (CH), 78.1 (CH), 73.8 (CH), 43.0 (CH2), 40.7 (CH2), 19.3 (Me); HRMS (FAB) m/z: [M – H]− calcd for C14H17O5, 265.1076; found, 265.1076.

2,6-Anhydro-1-(4-carboxyphenyl)-1,3-dideoxy-d-galacto-heptitol (17a)

Compound 17a was prepared according to general procedure B (yield, 51%; 3 steps). [α]D23 = 20.5 (c = 0.2, MeOH); 1H NMR (400 MHz, D2O): δ 7.74 (2H, d, J = 7.8 Hz), 7.21 (2H, d, J = 7.8 Hz), 3.59–3.45 (5H, m), 3.30 (1H, dd, J = 4.8, 7.2 Hz), 2.84 (1H, dd, J = 7.0, 13.9 Hz), 2.65 (1H, dd, J = 6.1, 13.8 Hz), 1.51 (1H, dd, J = 2.4, 11.1 Hz), 1.38 (1H, q, J = 12.0 Hz); 13C NMR (67.8 MHz, D2O): δ 173.5 (C), 147.0 (C), 132.4 (CH), 132.3 (CH), 130.7 (C), 81.3 (CH), 79.0 (CH), 71.6 (CH), 70.1 (CH), 64.3 (CH2), 43.7 (CH2), 35.7 (CH2); HRMS (FAB) m/z: [M – H]− calcd for C14H17O6, 281.1025; found, 281.1015.

2,6-Anhydro-1-(4-carboxyphenyl)-1,3,7-trideoxy-l-galacto-heptitol (20a)

Compound 20a was prepared according to general procedure B (yield, 27%; 3 steps). Compound 20a was isolated with a small amount of TBAF. [α]D23 = −7.9 (c = 0.3, MeOH); 1H NMR (400 MHz, D2O): δ 7.63 (2H, d, J = 8.2 Hz), 7.11 (2H, d, J = 8.2 Hz), 3.54–3.46 (2H, m), 3.34 (1H, d, J = 3.0 Hz), 3.30 (1H, q, J = 6.7 Hz), 2.71 (1H, dd, J = 7.1, 13.9 Hz), 2.55 (1H, dd, J = 6.3, 13.9 Hz), 1.41 (1H, ddd, J = 1.7, 4.8, 12.9 Hz), 1.29 (1H, q, J = 5.4 Hz), 0.92 (3H, d, J = 6.5 Hz); 13C NMR (67.8 MHz, D2O): δ 174.9 (C), 145.5 (C), 131.8 (CH), 131.7 (CH), 78.5 (CH), 76.5 (CH), 72.4 (CH), 71.4 (CH), 43.3 (CH2), 34.9 (CH2), 18.5 (Me); HRMS (FAB) m/z: [M – H]− calcd for C14H17O5, 265.1076; found, 265.1065.

2,6-Anhydro-1-(3-carboxyphenyl)-1,3,7-trideoxy-l-galacto-heptitol (20b)

Compound 20b was prepared according to general procedure B (yield, 20%; 3 steps). [α]D23 = −10.0 (c = 0.1, MeOH); 1H NMR (400 MHz, D2O): δ 7.68 (1H, s), 7.67 (1H, d, J = 7.9 Hz), 7.34 (1H, d, J = 7.4 Hz), 7.26 (1H, t, J = 7.5 Hz), 3.60–3.52 (2H, m), 3.40 (1H, d, J = 2.5 Hz), 3.35 (1H, q, J = 6.5 Hz), 2.77 (1H, dd, J = 7.0, 14.0 Hz), 2.60 (1H, dd, J = 6.3, 13.9 Hz), 1.46 (1H, dd, J = 4.2, 12.3 Hz), 1.33 (1H, q, J = 11.8 Hz), 0.98 (3H, d, J = 6.5 Hz); 13C NMR (67.8 MHz, D2O): δ 173.4 (C), 141.4 (C), 137.3 (CH), 132.9 (CH), 132.6 (C), 131.5 (CH), 130.5 (CH), 79.0 (CH), 76.9 (CH), 72.9 (CH), 71.8 (CH), 43.5 (CH2), 35.2 (CH2), 19.0 (Me); HRMS (FAB) m/z: [M + H]+ calcd for C14H19O5, 267.1232; found, 267.1223.

2,6-Anhydro-1-(4-carboxy-3-hydroxyphenyl)-1,3,7-trideoxy-l-galacto-heptitol (20j)

Compound 20j was prepared according to general procedure B (yield, 71%; 3 steps). [α]D23 = −7.4 (c = 0.4, MeOH); 1H NMR (400 MHz, D2O): δ 7.47 (1H, d, J = 7.9 Hz), 6.58 (1H, d, J = 9.3 Hz), 6.57 (1H, s), 3.53–3.40 (2H, m), 3.33 (1H, d, J = 3.0 Hz), 3.30 (1H, q, J = 6.6 Hz), 2.64 (1H, dd, J = 6.9, 13.9 Hz), 2.46 (1H, dd, J = 6.5, 13.9 Hz), 1.41 (1H, ddd, J = 1.4, 4.4, 12.8 Hz), 1.25 (1H, q, J = 12.1 Hz), 0.92 (3H, d, J = 6.4 Hz); 13C NMR (67.8 MHz, D2O): δ 177.6 (C), 161.9 (C), 147.0 (C), 132.8 (CH), 122.7 (CH), 119.1 (CH), 118.4 (C), 78.4 (CH), 76.5 (CH), 72.4 (CH), 71.3 (CH), 43.3 (CH2), 34.8 (CH2), 18.5 (Me); HRMS (FAB) m/z: [M – H]− calcd for C14H17O6, 281.1025; found, 281.1008.

General Procedure C: Deprotection, Followed by Hydrogenation–Acetylation

The solution of the coupled products 5a, 6a, 7a, or 8a (0.44 mmol) in THF (5.0 mL) was added to a 1.0 M THF solution of TBAF (5.0 mL, 5.0 mmol), and the reaction mixture was stirred at room temperature for several hours. The reaction was quenched with water (10 mL), and the mixture was extracted several times with EtOAc. The combined organic layers were washed with water, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain crude methyl ester 9a, 12a, 15a, or 18a. The solution of 9a, 12a, 15a, or 18a and 10% Pd/C (13 mg) in THF (5 mL) was stirred at room temperature under H2 for several hours. The catalyst was removed via filtration, and the filtrate was concentrated under reduced pressure to obtain crude 10a, 13a, 16a, or 19a. Crude 10a, 13a, 16a, or 19a in pyridine (1.0 mL) and Ac2O (1.0 mL) was stirred at room temperature for several hours. The reaction was quenched with water (10 mL), and the mixture was extracted several times with EtOAc. The combined organic layers were successively washed with water and 1 M HCl, and dried over anhydrous Na2SO4. After concentrating under reduced pressure, the residue was purified via silica gel chromatography to obtain 21a, 22a, 23a, or 24a.

4,5,7-Tri-O-acetyl-2,6-anhydro-1,3-dideoxy-1-[4-(methoxycarbonyl)phenyl]-d-gluco-heptitol (21a)

Compound 21a was prepared according to general procedure C (yield, 64%; 3 steps). [α]D23 = −4.3 (c = 1.1, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.96 (2H, d, J = 8.1 Hz, Ar), 7.28 (2H, d, J = 8.3 Hz, Ar), 5.00–4.91 (2H, m, H-3 and H-4), 4.25 (1H, dd, J = 5.3, 12.0 Hz, H-6), 4.06 (1H, dd, J = 2.2, 12.2 Hz, H-6), 3.91 (3H, s, OMe), 3.74–3.67 (1H, m, H-1), 3.55 (1H, ddd, J = 2.4, 5.6, 9.2 Hz, H-5), 2.99 (1H, dd, J = 6.8, 13.9 Hz, CH2Ar), 2.80 (1H, dd, J = 5.6, 13.9 Hz, CH2Ar), 2.11–2.03 (1H, m, H-2), 2.06 (3H, s, Ac), 2.03 (3H, s, Ac), 2.00 (3H, s, Ac), 1.53 (1H, q, J = 11.5 Hz, H-2); 13C NMR (67.8 MHz, CDCl3): δ 170.7 (C), 170.4 (C), 169.8 (C), 167.0 (C), 142.9 (C), 129.6 (CH), 129.5 (CH), 128.6 (C), 77.3 (CH), 75.8 (CH), 72.1 (CH), 69.4 (CH), 62.7 (CH2), 52.0 (Me), 41.4 (CH2), 35.9 (CH2), 20.9 (Me), 20.8 (Me), 20.7 (Me); HRMS (FAB) m/z: [M + H]+ calcd for C21H27O9, 423.1655; found, 423.1640.

4,5-Di-O-acetyl-2,6-anhydro-1,3,7-trideoxy-1-[4-(methoxycarbonyl)phenyl]-l-gluco-heptitol (22a)

Compound 22a was prepared according to general procedure C (yield, 67%; 3 steps). [α]D23 = −5.1 (c = 1.7, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.96 (2H, d, J = 8.1 Hz, Ar), 7.27 (2H, d, J = 8.3 Hz, Ar), 4.92 (1H, ddd, J = 5.2, 9.5, 11.6 Hz, H-3), 4.70 (1H, t, J = 9.4 Hz, H-4), 3.91 (3H, s, OMe), 3.71–3.65 (1H, m, H-1), 3.41 (1H, dq, J = 6.4, 9.6 Hz, H-5), 2.96 (1H, dd, J = 6.8, 13.8 Hz, CH2Ar), 2.76 (1H, dd, J = 5.8, 13.8 Hz, CH2Ar), 2.07 (1H, ddd, J = 1.7, 5.3, 12.8 Hz, H-2), 2.04 (3H, s, Ac), 1.99 (3H, s, Ac), 1.49 (1H, ddd, J = 11.6, 11.6, 11.6 Hz, H-2), 1.17 (3H, d, J = 6.0 Hz, H-6); 13C NMR (67.8 MHz, CDCl3): δ 170.4 (C), 170.1 (C), 167.0 (C), 143.1 (C), 129.6 (CH), 129.4 (CH), 128.5 (C), 75.3 (CH), 74.5 (CH), 73.9 (CH), 72.1 (CH), 52.0 (Me), 41.7 (CH2), 36.2 (CH2), 21.0 (Me), 20.8 (Me), 17.9 (Me); HRMS (FAB) m/z: [M + H]+ calcd for C19H25O7, 365.1600; found, 365.1583.

4,5,7-Tri-O-acetyl-2,6-anhydro-1,3-dideoxy-1-[4-(methoxycarbonyl)phenyl]-d-galacto-heptitol (23a)

Compound 23a was prepared according to general procedure C (yield, 31%; 3 steps). [α]D23 = 11.7 (c = 0.5, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.96 (2H, d, J = 8.2 Hz, Ar), 7.30 (2H, d, J = 8.4 Hz, Ar), 5.27 (1H, d, J = 3.1 Hz, H-4), 4.96 (1H, ddd, J = 3.1, 5.2, 11.8 Hz, H-3), 4.14 (1H, dd, J = 6.9, 11.2 Hz, H-6), 4.05 (1H, dd, J = 6.2, 11.5 Hz, H-6), 3.91 (3H, s, OMe), 3.76 (1H, t, J = 6.7 Hz, H-5), 3.73–3.67 (1H, m, H-1), 3.06 (1H, dd, J = 7.2, 13.8 Hz, CH2Ar), 2.81 (1H, dd, J = 5.6, 13.8 Hz, CH2Ar), 2.14 (3H, s, Ac), 2.01 (3H, s, Ac), 1.98 (3H, s, Ac), 1.78 (1H, q, J = 11.5 Hz, H-2), 1.71 (1H, ddd, J = 2.0, 4.9, 12.4 Hz, H-2); 13C NMR (67.8 MHz, CDCl3): δ 170.5 (C), 170.3 (C), 170.1 (C), 167.0 (C), 143.0 (C), 129.6 (CH), 129.5 (CH), 128.5 (C), 76.4 (CH), 74.4 (CH), 69.7 (CH), 66.1 (CH), 62.2 (CH2), 52.0 (Me), 41.8 (CH2), 31.3 (CH2), 20.8 (Me), 20.7 (Me); HRMS (FAB) m/z: [M + H]+ calcd for C21H27O9, 423.1655; found, 423.1640.

4,5-Di-O-acetyl-2,6-anhydro-1,3,7-trideoxy-1-[4-(methoxycarbonyl)phenyl]-l-galacto-heptitol (24a)

Compound 24a was prepared according to general procedure C (yield, 29%; 3 steps). [α]D23 = −19.2 (c = 0.1, CHCl3); 1H NMR (400 MHz, CDCl3): δ 7.97 (2H, d, J = 8.1 Hz, Ar), 7.30 (2H, d, J = 8.2 Hz, Ar), 5.12 (1H, d, J = 2.9 Hz, H-4), 4.94 (1H, ddd, J = 3.2, 5.5, 11.9 Hz, H-3), 3.91 (3H, s, OMe), 3.70–3.62 (2H, m, H-1, H5), 3.07 (1H, dd, J = 6.7, 13.6 Hz, CH2Ar), 2.79 (1H, dd, J = 6.4, 13.8 Hz, CH2Ar), 2.17 (3H, s, Ac), 1.97 (3H, s, Ac), 1.73 (1H, q J = 12.2 Hz, H-2), 1.66 (1H, ddd, J = 2.3, 5.4, 12.5 Hz, H-2), 1.16 (3H, d, J = 6.3 Hz, H-6); 13C NMR (67.8 MHz, CDCl3): δ 170.8 (C), 170.1 (C), 167.0 (C), 143.3 (C), 129.7 (CH), 129.4 (CH), 128.5 (C), 76.2 (CH), 72.8 (CH), 70.3 (CH), 69.3 (CH), 52.0 (Me), 42.1 (CH2), 31.0 (CH2), 20.9 (Me), 20.8 (Me), 16.9 (Me); HRMS (FAB) m/z: [M + H]+ calcd for C19H25O7, 365.1600; found, 365.1607.
  10 in total

1.  Stille coupling made easier-the synergic effect of copper(I) salts and the fluoride ion.

Authors:  Simon P H Mee; Victor Lee; Jack E Baldwin
Journal:  Angew Chem Int Ed Engl       Date:  2004-02-20       Impact factor: 15.336

Review 2.  SGLT2 inhibition--a novel strategy for diabetes treatment.

Authors:  Edward C Chao; Robert R Henry
Journal:  Nat Rev Drug Discov       Date:  2010-05-28       Impact factor: 84.694

Review 3.  Recent Advances in the Chemical Synthesis of C-Glycosides.

Authors:  You Yang; Biao Yu
Journal:  Chem Rev       Date:  2017-09-15       Impact factor: 60.622

4.  General Approach to Five-Membered Nitrogen Heteroaryl C-Glycosides Using a Palladium/Copper Cocatalyzed C-H Functionalization Strategy.

Authors:  Shuo Zhang; You-Hong Niu; Xin-Shan Ye
Journal:  Org Lett       Date:  2017-06-09       Impact factor: 6.005

Review 5.  Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.

Authors:  Wenqing Cai; Linlin Jiang; Yafei Xie; Yuqiang Liu; Wei Liu; Guilong Zhao
Journal:  Med Chem       Date:  2015       Impact factor: 2.745

Review 6.  Carbohydrate-mediated recognition systems in innate immunity.

Authors:  T Feizi
Journal:  Immunol Rev       Date:  2000-02       Impact factor: 12.988

7.  Synthesis of C-glycopyranosyl compounds by a palladium-catalyzed coupling reaction of 1-tributylstannyl-D-glucals with organic halides.

Authors:  E Dubois; J M Beau
Journal:  Carbohydr Res       Date:  1992-04-10       Impact factor: 2.104

8.  Synthesis of novel 2-deoxy-β-benzyl-C-glycosides by highly stereo- and chemoselective hydrogenation of exo-glycals.

Authors:  Gisela Díaz; Agustín Ponzinibbio; Rodolfo Daniel Bravo
Journal:  Carbohydr Res       Date:  2014-04-21       Impact factor: 2.104

9.  Room-temperature Stille cross-couplings of alkenyltin reagents and functionalized alkyl bromides that possess beta hydrogens.

Authors:  Karsten Menzel; Gregory C Fu
Journal:  J Am Chem Soc       Date:  2003-04-02       Impact factor: 15.419

10.  MOP and EE Protecting Groups in Synthesis of α- or β-Naphthyl-C-Glycosides from Glycals.

Authors:  Jan Choutka; Radek Pohl; Kamil Parkan
Journal:  ACS Omega       Date:  2018-07-16
  10 in total
  1 in total

1.  Investigation of the Selectivity of the Palladium-Catalyzed Aroylation and Arylation of Stannyl Glycals with Aroyl Chlorides.

Authors:  Tsuyoshi Shinozuka
Journal:  ACS Omega       Date:  2021-03-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.